Avadel Pharmaceuticals rises as FDA expands approval for sleep disorder drug

Avadel Pharmaceuticals

17/10/2024 15:08

** Shares of Avadel Pharmaceuticals  AVDL.O  rise 3.55% to
$13.71
    ** Co says FDA expanded the use of its drug Lumryz to treat
sudden muscle weakness called cataplexy or excessive daytime
sleepiness in patients 7 years of age and older with narcolepsy
    ** The drug was approved for adults in 2023
    ** Narcolepsy is a chronic neurological disorder that
affects the brain's ability to control sleep and wake cycles
    ** Shares down ~4% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))